Bruker Co. Announces Quarterly Dividend of $0.04 (BRKR)

Bruker Co. (NASDAQ:BRKR) announced a quarterly dividend on Tuesday, February 20th, Zacks reports. Shareholders of record on Tuesday, March 6th will be given a dividend of 0.04 per share by the medical research company on Friday, March 23rd. This represents a $0.16 annualized dividend and a dividend yield of 0.51%. The ex-dividend date is Monday, March 5th.

Bruker (NASDAQ BRKR) traded down $0.57 on Wednesday, hitting $31.53. The company’s stock had a trading volume of 378,400 shares, compared to its average volume of 545,783. Bruker has a 1 year low of $21.83 and a 1 year high of $36.53. The firm has a market cap of $4,993.56, a P/E ratio of 64.35, a price-to-earnings-growth ratio of 2.13 and a beta of 1.05. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, February 8th. The medical research company reported $0.51 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.02. Bruker had a return on equity of 26.58% and a net margin of 4.45%. The firm had revenue of $530.50 million for the quarter, compared to the consensus estimate of $506.74 million. During the same quarter last year, the business posted $0.46 EPS. The company’s revenue for the quarter was up 12.8% on a year-over-year basis. research analysts expect that Bruker will post 1.37 EPS for the current year.

BRKR has been the topic of a number of recent research reports. BTIG Research initiated coverage on Bruker in a research report on Friday, January 5th. They issued a “buy” rating and a $42.00 target price on the stock. Zacks Investment Research raised Bruker from a “hold” rating to a “buy” rating and set a $39.00 target price on the stock in a research report on Thursday, January 4th. BidaskClub downgraded Bruker from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 11th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $35.00 target price on shares of Bruker in a research report on Thursday, December 14th. Finally, Cowen reaffirmed a “hold” rating and issued a $35.00 target price on shares of Bruker in a research report on Thursday, December 21st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $32.62.

An institutional investor recently raised its position in Bruker stock. The Manufacturers Life Insurance Company raised its position in shares of Bruker Co. (NASDAQ:BRKR) by 7.1% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,003 shares of the medical research company’s stock after acquiring an additional 331 shares during the period. The Manufacturers Life Insurance Company ‘s holdings in Bruker were worth $144,000 at the end of the most recent quarter. Institutional investors and hedge funds own 65.89% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Dividend History for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with's FREE daily email newsletter.

Leave a Reply